论文部分内容阅读
幽门螺杆菌(HP)与慢性胃炎、消化性溃疡、胃癌的发生发展关系密切,已被国际抗癌机构列为Ⅰ类致癌物。目前药物对HP根治率为90%左右,部分患者由于用药不规范,使耐药HP发生率呈上升趋势。笔者就克菌(羟氨苄青霉素+双氯青霉素)治疗羟氢苄青霉素(Amo)耐药的HP进行了实验研究,现报道如下。
Helicobacter pylori (HP) is closely related to the occurrence and development of chronic gastritis, peptic ulcer and gastric cancer and has been classified as Class I carcinogen by the International Anti-Cancer Agency. The current drug cure rate of about 90% of HP, some patients due to non-standard medication, the incidence of drug-resistant HP is on the rise. The author of gram bacteria (amoxicillin + dicloxacillin) treatment of hydroxybenzamycin (Amo) resistance of HP conducted an experimental study are reported below.